Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.42 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | TYMS | P04818 | 1/20 | 0.41 |
| ▸ | RGS4 | P49798 | 1/20 | 0.40 |
| ▸ | PNP | P00491 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.40 |
| ▸ | PDE1A | P54750 | 3/20 | 0.40 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579583 | 0.83 | SMN1; SMN2 (0.46) | ALDH1A1MAPTPDE1BPDE1APDE1C | |
| SCHEMBL3576115 | 0.82 | DCTPP1 (0.47) | KDM4EALDH1A1MAPTALOX15GAA | |
| SCHEMBL13349110 | 0.81 | PDE1B (0.37) | KDM4EALDH1A1MAPTALOX15AADAT | |
| SCHEMBL17459011 | 0.78 | MEN1 (0.49) | KDM4EALDH1A1MAPTALOX15GAA | |
| SCHEMBL7258447 | 0.74 | MEN1 (0.47) | KDM4EALDH1A1MAPTALOX15AADAT | |
| SCHEMBL3588294 | 0.73 | TP53 (0.48) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL29670548 | 0.73 | GAA (0.52) | KDM4EALDH1A1MAPTALOX15GAA | |
| SCHEMBL25027880 | 0.72 | PTGS2 (0.45) | KDM4EALDH1A1MAPTALOX15AADAT | |
| SCHEMBL4100807 | 0.70 | ALDH1A1 (0.49) | ALDH1A1ALOX15GAAAADATCMA1 | |
| SCHEMBL15652306 | 0.69 | KDM4E (0.46) | KDM4EALDH1A1MAPTALOX15GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160324-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
| US-20100160324-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
| US-20100160324-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
| EP-1836188-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | Astex Therapeutics Limited (GB) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006070198-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160324-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | CDK1, CDK3, CDK13 | KDM4E 990/4885ALDH1A1 3914/4885MAPT 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.